NCT01152567已完成不适用
Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 50,000
- 试验地点
- 1
- 主要终点
- Investigate the risk of Cardiovascular Disease (CVD) and new onset diabetes in patients on primary hypertensive treatment with ACE or candesartan for hypertension
研究概览
简要总结
The planned Study will be a retrospective study on the effect of ACE's vs. candesartan on cardiovascular events and on health economic effects in a "real life" setting in Sweden.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 17 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all patients found in electronic patient journals at the participating centres, who were prescribed either ACEis (ATC-C09A-B) or ARBs (C09C-D) for hypertension from 1 January 1999 - 31 December
- •The first date of such a prescription starts the observation time and is called the index prescription.
排除标准
- •No history of cardiovascular disease.
- •Ongoing malignancy
结局指标
主要结局
Investigate the risk of Cardiovascular Disease (CVD) and new onset diabetes in patients on primary hypertensive treatment with ACE or candesartan for hypertension
时间窗: Time to first CV event calculated as the time (in days) between date of index prescription and date of the first registration of a CV event. Patients will be followed for min. 1 wk and up to 9 yrs (1999-2007). Median follow up time is estimated to 2 yrs.
次要结局
- To investigate the risk of CVD and new onset diabetes in patients treated with specific types of ACEi or candesartan for hypertension(Time to first CV event calculated as the time (in days) between date of index prescription and date of the first registration of a CV event. Patients will be followed for min. 1 wk and up to 9 yrs (1999-2007). Median follow up time is estimated to 2 yrs.)
- To investigate the risk of hypertensive organ damage, renal failure and hyperlipidemia for patients treated with ACEi or candesartan(Time to first CV event calculated as the time (in days) between date of index prescription and date of the first registration of a CV event. Patients will be followed for min. 1 wk and up to 9 yrs (1999-2007). Median follow up time is estimated to 2 yrs.)
- Evaluate differences in use of health care resources, and assess the potential long term cost effectiveness(Differences in health care consumption will be estimated through models incorporating normalised costs, level of care, age, gender and study year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel InflammationCoronary DiseaseAtherosclerosisVasculitisNCT00005928National Heart, Lung, and Blood Institute (NHLBI)25
终止
不适用
ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty PatientsAdverse Effects of Angiotensin-converting-enzyme InhibitorsHypotensionNCT01867047Duke University59
已完成
4 期
Effects of Aceis on Peritoneal Protein Loss and Solute Transport in pd PatientsDisorders Associated With Peritoneal DialysisNCT01575652Turkish Nephrology Association43
已完成
3 期
Angiotensin-converting-enzyme (ACE) Inhibitors in HemodialysisLeft Ventricular HypertrophyHypertensionNCT00985322Mario Negri Institute for Pharmacological Research269
已完成
不适用
Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type two diabetes mellitusType two Diabetes Mellitus (DM)Nutritional, Metabolic, EndocrineDiabetes mellitusISRCTN76608550Heraklion University Hospital (Greece)62